Highlights from EHA

June 16, 2022

From 9th to 17st June, the Acute Leukemia Advocates Network (ALAN) attended the 27th European Hematology Association (EHA) congress, held for the hybrid, with a F2F part from 9th to 12th June and a virtual part from 15th to 17th June. We had the chance to be in Vienna for the F2F component as well as attending online when we came back.

Here is what we took away from the various sessions.

Focus on AML

Patients with AML belong to the highest risk group for developing invasive fungal disease (IFD) at diagnosis or during treatment course. Relevant entities of IFD in this population include invasive candidiasis and candidemia mostly acquired through fungal translocation of commensal yeasts from the lumen of the gastrointestinal tract via the mucosal barrier, whereas invasive mold infections are acquired through airborne inhalation of fungal conidia, airway germination, and subsequent dissemination. These entities affect profoundly neutropenic patients.

To address those questions, EHA gathered an expert group in 2019 to give recommendations for clinical management in cooperation with the Cochrane Haematology Group. For the resulting guideline, studies including all relevant novel-targeted agents and antifungal agents were reviewed, summarized and—depending on available studies—evidence-based or consensus-based recommendations were phrased.

Summary of Recommendations Regarding Antifungal Prophylaxis for Clinically Relevant Antileukemic Drugs can be found here: summary of recommendations

Focus on ALL


Additional resources to check

Recommendations for the top abstracts to look out for in AML. See post here: https://aml-hub.com/medical-information/eha2022-abstracts-what-s-hot-in-aml

Recommendations for the top abstracts to look out for in ALL. See post here: https://lymphoblastic-hub.com/medical-information/eha-2022-abstracts-what-s-hot-in-all